The clinical mass spectrometry market will register a CAGR of almost 8% by 2023.

Increase in the use of hyphenated technology will drive growth in the market. Personalized medicine refers to providing medical treatment according to the individual characteristics of patients. Personalized medicine, a multi-faceted approach to patient care, improves the ability to diagnose and treat disease and offers the potential to detect diseases at an earlier stage when treatment can be effective.

Rise in aging population

The global clinical mass spectrometry market is observing a boost in demand due to the surge in average age due to the rising life expectancy leading to a larger aging population across the globe.

High cost of instrument

Clinical mass spectrometry technologies with specific and advanced features are expensive to procure and maintain, which can restrict their adoption. Thus, this cost of instrumentation is likely to hamper the growth of the market.

Competitive Landscape

With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.

Market Trends

  • Increasing Demand for Clinical Mass Spectrometry in Personalized Medicine
  • Increasing Demand for Portable Clinical Mass Spectrometry
  • Technological Advances

Key Players

  • Agilent Technologies
  • Bruker
  • Danaher
  • PerkinElmer
  • Thermo Fisher Scientific
  • Waters

Topics Covered

1. Executive Summary

2. Scope of the Report

3. Market Landscape

4. Market Sizing

5. Five Forces Analysis

6. Market Segmentation by End-User

7. Customer Landscape

8. Geographic Landscape

9. Decision Framework

10. Drivers and Challenges

11. Market Trends

12. Vendor Landscape

13. Vendor Analysis

For more information about this report visit here.